439580
BLUEMTEC Co., Ltd. operates a pharmaceutical distribution platform in South Korea and internationally. It is also involved in the healthcare digital marketing, IT development, fulfilment, pharmaceutical distribution data, and medical staff matching, and logistics businesses. The company was founded in 2015 and is headquartered in Yongin, South Korea.
439580 (439580) - Net Assets
Latest net assets as of March 2025: ₩45.58 Billion KRW
Based on the latest financial reports, 439580 (439580) has net assets worth ₩45.58 Billion KRW as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩109.40 Billion) and total liabilities (₩63.82 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩45.58 Billion |
| % of Total Assets | 41.66% |
| Annual Growth Rate | 531.76% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1875.63 |
439580 - Net Assets Trend (2022–2024)
This chart illustrates how 439580's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 439580 (2022–2024)
The table below shows the annual net assets of 439580 from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩47.14 Billion | +3.79% |
| 2023-12-31 | ₩45.41 Billion | +3755.05% |
| 2022-12-31 | ₩1.18 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to 439580's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3285579569000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩9.21 Billion | 19.53% |
| Common Stock | ₩1.12 Billion | 2.37% |
| Other Components | ₩36.81 Billion | 78.10% |
| Total Equity | ₩47.14 Billion | 100.00% |
439580 Competitors by Market Cap
The table below lists competitors of 439580 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JASTECH Ltd
KQ:090470
|
$53.41 Million |
|
AS Tallink Grupp
F:T5N
|
$53.42 Million |
|
Nanoform Finland Plc
HE:NANOFH
|
$53.44 Million |
|
Gabriel Holding
CO:GABR
|
$53.44 Million |
|
Impiana Hotels Bhd
KLSE:7243
|
$53.39 Million |
|
CrystalGenomics Inc
KQ:083790
|
$53.38 Million |
|
Ideal Finansal Teknolojiler ve Danismanlik Anonim Sirketi
IS:SKYLP
|
$53.38 Million |
|
Taiwan Steel Union Co Ltd
TW:6581
|
$53.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 439580's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 45,414,636,870 to 47,137,038,660, a change of 1,722,401,790 (3.8%).
- Net loss of 4,802,079,400 reduced equity.
- Share repurchases of 659,237,800 reduced equity.
- Other factors increased equity by 7,183,718,990.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-4.80 Billion | -10.19% |
| Share Repurchases | ₩659.24 Million | -1.4% |
| Other Changes | ₩7.18 Billion | +15.24% |
| Total Change | ₩- | 3.79% |
Book Value vs Market Value Analysis
This analysis compares 439580's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.56x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 97.77x to 2.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩36.87 | ₩3605.00 | x |
| 2023-12-31 | ₩1421.39 | ₩3605.00 | x |
| 2024-12-31 | ₩1406.61 | ₩3605.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 439580 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.60%
- • Asset Turnover: 1.15x
- • Equity Multiplier: 2.45x
- Recent ROE (-10.19%) is above the historical average (-407.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -1208.35% | -18.45% | 1.91x | 34.26x | ₩-14.35 Billion |
| 2023 | -5.16% | -2.06% | 1.23x | 2.03x | ₩-6.88 Billion |
| 2024 | -10.19% | -3.60% | 1.15x | 2.45x | ₩-9.52 Billion |
Industry Comparison
This section compares 439580's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
No peer company data available for comparison.